CCR4-positive Adult T-cell leukemia/lymphoma CCR4-positive Peripheral T-cell lymphoma Cutaneous T-cell lymphoma
Conditions
Interventions
None listed
Sponsors
Kyowa Kirin Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients whose data was recorded participating the following clinical trials: Phase 2 trial investigating mogamulizumab efficacy and safety for relapsed ATL patients Phase 2 trial comparing mogamulizumab efficacy and safety with investigator's choice for relapsed/refractory ATL patients Phase 2 clinical trial comparing efficacy and safety of mLSG15+mogamulizumab combination therapy with mLSG15 alone for untreated ATL patients Phase 2 trial investigating mogamulizumab efficacy and safety for relapsed PTCL patients Phase 2 trial investigating mogamulizumab efficacy and safety for relapsed/refractory PTCL patients Phase 1/2 trial investigating mogamulizumab efficacy and safety for relapsed/refractory CTCL patients Phase 3 trial comparing mogamulizumab efficacy and safety with vorinostat for relapsed/refractory CTCL patients
Exclusion criteria
Exclusion criteria: Patients participated the below trials but did not take mogamulizumab administration. Phase 2 trial comparing mogamulizumab efficacy and safety with investigator's choice for relapsed/refractory ATL patients Phase 3 trial comparing mogamulizumab efficacy and safety with vorinostat for relapsed/refractory CTCL patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood parameter changes | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma concentration changes of mogamulizumab Generalized models of blood parameters | — |
Countries
Japan,North America,South America,Europe
Contacts
Public ContactYukihiro Nishio
Kyowa Kirin Co., Ltd. Medical Affairs
Outcome results
None listed